背景(考古学)
血库
移植
业务
粪便细菌疗法
捐赠
立法机关
服务(商务)
医学
营销
外科
生物
医疗急救
经济
政治学
抗生素
艰难梭菌
法学
古生物学
微生物学
经济增长
作者
Maja Skov Kragsnæs,Anna Christine Nilsson,Jens Kjeldsen,Hanne Marie Holt,Kristina Fruerlund Rasmussen,Jørgen Georgsen,Torkell Ellingsen,Dorte Kinggaard Holm
出处
期刊:Transfusion
[Wiley]
日期:2020-05-28
卷期号:60 (6): 1135-1141
被引量:13
摘要
Worldwide, there is a rising demand for thoroughly screened, high‐quality fecal microbiota transplantation (FMT) products that can be obtained at a reasonable cost. In the light of this evolving therapeutic area of the intestinal microbiota, both private and public stool banks have emerged. However, some of the larger difficulties when establishing stool banks are caused by the absence of or international disagreement on regulation and legislative formalities. In this context, the establishment of a stool bank within a nonprofit blood and tissue transplant service has several advantages. Especially, this setting can ensure that every step of the donation process, laboratory handling, and donor‐traceability is in agreement with the current expert guidelines and meets the requirements of the European Union's regulative directives on human cells and tissues. Although safety and documentation are the top priority of the stool bank setup presented here, cost‐effectiveness of the production is possible due to a high donor screening success rate and the knowhow, infrastructure, facilities, personnel, and laboratory‐ and quality‐management systems that were already in place. Overall, our experience is that a centralized, nonprofit, blood and tissue transplant service is an ideal and safe facility to run a stool bank of high quality FMT products that are based on stool donations from volunteer, unpaid, healthy, blood donors.
科研通智能强力驱动
Strongly Powered by AbleSci AI